EUSOL vs. PDGF Dressing for Diabetic Foot Ulcers

Comparison of EUSOL Dressing Versus Platelet Derived Growth Factor Dressing in Wound Contraction of Grade II Wagner Diabetic Foot Ulcers: A Randomized Controlled Trial

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07493343

Enrollment

120

Registered

2026-03-25

Start date

2020-01-01

Completion date

2026-01-10

Last updated

2026-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Wound

Keywords

Diabetic Foot Ulcer, Wagner Grade II, Wound Healing, Platelet-Derived Growth Factor, EUSOL

Brief summary

Diabetic foot ulcers are a major cause of morbidity and amputation. This randomized controlled trial will compare the efficacy of a traditional antiseptic dressing (EUSOL) with a modern biologic dressing containing Platelet-Derived Growth Factor (PDGF) in promoting wound contraction. The study aims to determine if PDGF dressing leads to better healing outcomes in patients with Grade II Wagner diabetic foot ulcers.

Interventions

PROCEDUREEUSOL Dressing

Daily dressing with freshly prepared Edinburgh University Solution of Lime (EUSOL) applied to the ulcer after standard debridement and cleansing.

PROCEDUREPlatelet-Derived Growth Factor (PDGF) Dressing

PDGF-based topical preparation applied to the ulcer surface every fourth day, covered by a secondary dressing. Interim dressing changes used normal saline only.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of diabetes mellitus. * Presence of a Grade II Wagner diabetic foot ulcer (penetrating to subcutaneous tissue, without involvement of tendon, bone, or joint). * Ulcer size less than 6 x 6 cm at baseline.

Exclusion criteria

* Uncontrolled diabetes * Malnourished (BMI less than 20) * HB less than 10 * ABPI less than 0.9 * Immunosuppression therapy * Patients with malignancy or uncontrolled cardiopulmonary, neurological, or psychiatric disease. * Severe active infection

Design outcomes

Primary

Measure	Time frame	Description
Proportion of patients achieving wound contraction.	4 weeks	Wound healing will be defined as the achievement of at least a 50% reduction in ulcer area from baseline after four weeks of treatment. Ulcer area will be calculated as maximum length multiplied by maximum width.

Countries

Pakistan

Contacts

STUDY_DIRECTORAwais Amjad Malik, MBBS, FCPS

Services Institute of Medical Sciences

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026